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In community-acquired pneumonia (CAP), the cortisol level on admission can be a useful
biomarker for prognosis. Serial cortisol measurements during the clinical course of disease
and their association with disease outcome have never been reported. Furthermore, the time
to recovery of the hypothalamic-pituitary-adrenal axis after a short course of dexamethasone
during infection is unclear.
We analyzed data from 270 hospitalized patients with CAP. Total serum cortisol was
measured on presentation, day 1, 2, 4, and on control visit (day 30). Intensive care unit
(ICU) admission and mortality were assessed. Additionally, to study the influence of dexameth-
asone on the kinetics of the cortisol response, we analyzed serial cortisol values of 43 patients
treated with a four-day regimen of dexamethasone 5 mg.
During hospital stay, 26/270 patients (9.6%) were admitted to the ICU and 15/270 patients
(5.6%) died. Compared to patients with an uneventful recovery, cortisol on presentation wasof Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Heidelberglaan 100,
Netherlands. Tel.: þ31 88 7550807; fax: þ31 30 2523741.
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906 H.H.F. Remmelts et al.significantly higher in patients with an adverse outcome (360 mg/L, IQR 209-597 vs. 238 mg/L,
IQR 151-374) (p:0.01), and also remained significantly higher throughout the course of disease.
Dexamethasone treatment resulted in nearly complete suppression of the endogenous cortisol
production after the first dose, but cortisol production was fully recovered on control visit.
In conclusion, we showed that an adverse outcome of CAP was associated with persisting
higher total serum cortisol throughout the course of disease. Delta-cortisol could be another
meaningful biomarker in CAP. Next, our data indicate that a four-day dexamethasone regimen
during CAP does not lead to prolonged secondary adrenal insufficiency.
ª 2012 Elsevier Ltd. All rights reserved.Figure 1 Changes in serum cortisol in hospitalized patients
with community-acquired pneumonia. Total serum cortisol
levels are shown for patients with an uneventful recovery
(panel A) and for patients who died or were admitted to the
ICU (panel B). Data points for individual patients are shown;
horizontal bars indicate median values. Asterisks indicate
a significant difference (p < 0.05) between both groups on
corresponding days.Main text
Cortisol, the predominant corticosteroid secreted by the
adrenal cortex, is an important endogenous regulator of
inflammation. During an infectious episode, cortisol
production increases, and exerts anti-inflammatory and
immunosuppressive activities.1 In patients with community-
acquired pneumonia (CAP), a high serum cortisol at the
moment of hospital admission is associated with an adverse
outcome.2 Therefore, cortisol could be a useful biomarker
for prognosis in CAP. To our knowledge, serial cortisol
measurements over the course of disease and their asso-
ciation with disease outcome have never been reported.
Synthetic corticosteroids are attractive as adjuvant therapy
in CAP, although conflicting data have been published. A
potential risk of corticosteroids is secondary adrenal
insufficiency.3 The time to recovery of the hypothalamic-
pituitary-adrenal (HPA) axis after a short course of dexa-
methasone during infection is unclear. For these reasons,
we determined serum cortisol in patients with CAP on
hospital admission and during the clinical course, until
patients were recovered.
We analyzed data from two clinical studies carried out in
two teaching hospitals in the Netherlands. Both studies
enrolled patients with confirmed pneumonia, using iden-
tical inclusion criteria. The study methods have been
described previously.4,5 Patients who were immunocom-
promised, on immunosuppressive therapy (including oral
corticosteroids), or who required immediate admission to
the intensive care unit (ICU) were excluded. For the
present study, patients using oral contraceptives, ketoco-
nazole, or patients receiving corticosteroids during hospital
stay were also excluded. Additionally, we analyzed 43
randomly selected patients receiving dexamethasone as
part of a clinical trial to explore the effect of dexametha-
sone on cortisol. Total serum cortisol was measured on
presentation, on day 1, 2, and 4 (at 8 A.M.), and on control
visit on day 30 by immunoassay (Calbiotech, Spring Valley,
USA). Statistical analyses were performed using SPSS 18.0
(Chicago, USA). A two-tailed p-value <0.05 was considered
significant. Patients were excluded from the study after ICU
admission. We measured differences in cortisol, albumin
and C-reactive protein (CRP) with the Students T-test or the
ManneWhitney U test as appropriate. Logistic regression
was used to assess possible confounding between variables.
270 patients were analyzed (mean age 62.3  18.0
years; 60% male). The mean pneumonia severity index (PSI)
score was 86.5  35.5 and 107/270 patients (40%) wereclassified as PSI class IV-V. Patients presented at the
hospital at any given moment of the day. The cortisol level
on presentation therefore could be biased by circadian
effects. However, during critical illness the circadian
rhythm is expected to be overridden.6 To determine
whether the circadian rhythm of cortisol was lost on
presentation, the time of cortisol measurement was plotted
against the height of cortisol. Subsequently, the Krus-
kaleWallis test was used to test for differences in height of
cortisol. Indeed, we found no association between cortisol
level and time of the day (p:0.51). Cortisol was higher in
patients with inhaled corticosteroids at home (305 mg/L,
IQR 176-527), compared to without (231 mg/L, IQR 153-374)
(p:0.03).
During hospital stay, 26/270 patients (9.6%) were
admitted to the ICU and 15/270 patients (5.6%) died.
Cortisol on presentation was significantly higher in patients
who died or were admitted to the ICU (n Z 34, 360 mg/L,
IQR 209-597), compared to patients with an uneventful
recovery (238 mg/L, IQR 151-374) (p:0.01). This was inde-
pendent of the use of inhaled corticosteroids at home.
Serum albumin did not differ significantly between both
groups (41.1  9.3 g/L vs. 43.6  7.6 g/L) (p:0.09). In
patients with an adverse outcome cortisol remained
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compared to patients with an uneventful recovery (Fig. 1).
Based on the association between the course of cortisol
during CAP and clinical outcome, we hypothesized that the
change in serum cortisol from day 0 to day 1, 2 or 4 (delta
(D) cortisol 0-1, 0-2, or 0-4) could be a better prognostic
biomarker in CAP. To assess the predictive value of D-
cortisol, Receiver Operator Characteristics (ROC) curve
analysis was performed. D-cortisol 0-4 appeared to be the
best predictor for adverse clinical outcome (AUC 0.73, 95%
CI 0.53e0.93), followed closely by D-cortisol 0-2 (AUC 0.72,
95% CI 0.56e0.89). The additional predictive value of D-
cortisol to the initial cortisol level or other biomarkers or
clinical scores was calculated using binary regression and
ROC curve analysis. When D-cortisol 0-4 or D-cortisol 0-2
was added to the cortisol level on presentation, the prog-
nostic accuracy improved substantially (Table 1). Moreover,
the predictive value of other commonly used biomarkers
and clinical scores in CAP also improved considerably when
D-cortisol 0-4 or D-cortisol 0-2 was added (Table 1).
In order to study the influence of dexamethasone on the
kinetics of the cortisol response, 43 randomly selected
patients treated with dexamethasone were analyzed in
detail. These patients received a four-day course of dexa-
methasone 5 mg intravenously once a day during hospital
stay, starting on the day of presentation. We analyzed the
decrease of cortisol from day 0 to day 2 because all patients
were at least 24 h on dexamethasone on day 2. As expec-
ted, dexamethasone treatment resulted in nearly complete
suppression of endogenous cortisol production in allTable 1 Prediction of adverse clinical outcome
(combined endpoint mortality/ICU admission) in
community-acquired pneumonia: results from Receiver
Operator Characteristics (ROC) curve analysis.
Parameter Number of
patients
(total
n Z 270)
AUC 95% CI
Cortisola 266 0.63 0.53e0.74
Cortisola & D-cortisol 0-1 226 0.68 0.54e0.83
Cortisola & D-cortisol 0-2 218 0.81 0.71e0.91
Cortisola & D-cortisol 0-4 186 0.88 0.81e0.94
CRPa 270 0.65 0.55e0.75
CRPa & D-cortisol 0-1 226 0.66 0.53e0.79
CRPa & D-cortisol 0-2 218 0.73 0.56e0.90
CRPa & D-cortisol 0-4 186 0.75 0.52e0.98
CURB-65a 205 0.66 0.55e0.76
CURB-65a & D-cortisol 0-1 173 0.71 0.60e0.83
CURB-65a & D-cortisol 0-2 161 0.76 0.59e0.92
CURB-65a & D-cortisol 0-4 142 0.70 0.51e0.88
PSI scorea 270 0.74 0.64e0.84
PSI scorea & D-cortisol 0-1 226 0.77 0.67e0.88
PSI scorea & D-cortisol 0-2 218 0.80 0.67e0.93
PSI scorea& D-cortisol 0-4 186 0.77 0.63e0.91
Abbreviations: AUC, area under the curve; CI, confidence
interval; CRP, C-reactive protein; CURB-65, CURB-65 Severity
Score for Community-Acquired Pneumonia; D, delta; PSI score,
Pneumonia Severity Index score.
a Measured on the day of presentation.patients (mean decrease of 87%). Cortisol levels on day 30
(range 25e35) were within the normal physiological range,
without apparent differences between the dexamethasone
and the control group (69 mg/L, IQR 45-110 vs. 67 mg/L, IQR
44-106) (p:0.87). Both groups had low CRP concentrations
on day 30 (5.9  8.1 mg/L vs. 7.4  12.8 mg/L) (p:0.61),
indicating resolution of inflammation. These data indicate
that a four-day dexamethasone regimen does not lead to
prolonged secondary adrenal insufficiency.
We are the first to report serial total serum cortisol
measurements during the course of disease in patients
hospitalized with CAP, together with its predictive value.
Our study showed that persisting higher cortisol throughout
the course of CAP is associated with adverse clinical
outcome. Although we have found that serial cortisol
measurements can add prognostic value to other
biomarkers and clinical scores for prognosis in CAP, its
clinical relevance remains to be further substantiated. D-
cortisol 0-2 or D-cortisol 0-4 as a biomarker has the disad-
vantage that the prediction of mortality/ICU admission will
be delayed by 2e4 days. From that perspective, biomarkers
and clinical scores that can be used on the day of presen-
tation are to be preferred. However, D-cortisol might be
helpful in patients without clinical improvement after the
first days of treatment. No change, or even an increase in
serum cortisol, is indicative of an unfavourable outcome,
and might help in the decision-making to switch or extend
therapy.
Previous studies that addressed the influence of
corticosteroids on the HPA axis were not performed in
patients with CAP, and various durations of therapy were
combined for analysis, which makes extrapolation of the
results to clinical practice difficult.3,7 In the present
study, a fixed dexamethasone regimen was used, enabling
us to determine the effects of short-term therapy more
reliably.
Some limitations of our study must be named. First,
our study has not been designed to study cortisol
responses as a primary endpoint, and therefore cortisol
was measured on day 0 and 30 at a random moment of the
day. However, this did not influence our day 0 cortisol
levels, because the circadian rhythm of cortisol was lost
on presentation. On day 30, the time of cortisol
measurement was similar for both groups. Second,
recovery of the HPA axis as measured by total serum
cortisol possibly paints an incomplete picture. Ideally,
Synacthen tests should have been performed. Finally,
patients were excluded when admitted to the ICU. We
therefore could not analyze the complete course of
cortisol in patients with an adverse outcome.
In conclusion, we showed that an adverse outcome of
CAP was associated with persisting increased total serum
cortisol levels throughout the course of disease. Delta-
cortisol could be another meaningful biomarker in CAP.
This finding may aid in the further development of
cortisol as a biomarker for prognosis in CAP. Next, we
found that adjuvant dexamethasone therapy almost
completely suppressed the endogenous cortisol produc-
tion after the first dose, but cortisol production was fully
recovered on day 30. These findings are particularly
relevant for clinical practice because adjuvant treatment
908 H.H.F. Remmelts et al.strategies in CAP are emerging, and corticosteroids
appear to be a promising candidate.
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